We therefore analyzed psoriasis patients before starting established systemic therapy (targeting IL-17A, IL-23, TNF-α, IL-12/23, and DMF) and for a follow-up up to 16 weeks in a single-center prospective study. This evidence concerns the gene IL37 and psoriasis.